Evidence Strategy (HEOR)

Proven expertise in high-impact, high-value therapies with high unmet need across Pharma, Biotech and MedTech

Deep familiarity with first-to-market launches, especially in life-saving therapies for pediatric conditions and rare diseases

Creative and impactful evidence generation that differentiates products in crowded, competitive therapeutic areas (TAs)

Stellar track record in conducting RWE studies, successfully bringing them to publication and pull-through to support Market Access and Strategic Pricing

Clear demonstration of prior success in driving access for patients and reducing payer barriers for approval

In today’s global life sciences marketplace, the role and value of evidence is unquestionable. Novel therapies—many of which might be high-value therapeutics and/or specialty drugs—will need compelling evidence to persuade physicians to write the script and payers to provide access to label.

Pre-launch, clients need to characterize the disease landscape, identify unmet needs, create pre-launch medical education and conduct market-shaping activities.

Post-launch, therapies will need to continue to produce evidence of real-world value. Compelling evidence is especially needed in crowded, highly competitive TAs to demonstrate differential value versus other therapies.

Without high-quality evidence, commercial objectives suffer—market access can be sub-optimal, KOL advocacy can be weak and the product’s potential could be severely limited.

Trinity Evidence Strategy helps clients demonstrate the holistic value of their assets across the product lifecycle by leveraging a best-in-class methodological approach powered by technology and scientifically-driven, publication-quality primary and secondary research.

With markets growing increasingly competitive across the globe, the challenge for Med Affairs and HEOR teams is four-fold:

Trinity’s Evidence Strategy team offers a complete suite of HEOR and Med Affairs services to help differentiate the value of a product vs. the competition.

Trinity’s HEOR Core Pillars of Excellence

3 areas of deep expertise across 8 core engagement types

Evidence Planning | Evidence Generation and Execution | Scientific Dissemination

Trinity’s Evidence Strategy team helps clients design a compelling value story, demonstrate must-have evidence and drive scientific dissemination

• Answering Important Business Questions

  Trinity’s integrated RWE and Evidence Strategy teams have collaboratively helped hundreds of clients address their most important business questions:

  • What are the unmet needs in the current treatment paradigm for Disease X?
  • What is the epidemiology of Disease X? Are there sub-types of interest?
  • How do I identify the right patients in the absence of ICD-9 / 10 codes?
  • What is the patient journey for someone suffering from Disease Y?
  • What are the treatment patterns, therapy use, switch / adherence behaviors?
  • What is the comparative effectiveness of therapies in this market / class?
  • What SE and AE are associated with these treatments?
  • What is the overall Healthcare Resource Utilization (HCRU)?
  • What is the holistic cost of care?
  • Strategically, what are the pain points, unmet needs and gaps where Treatment Z can add value?

  Find out more about Trinity EvidenceFirst – Helping clients navigate through the complexities of RWE analysis.

Trinity supports a broad array of high-impact scientific publications

Collaboration between HEOR and Medical Affairs helps organizations optimize value, access and patient outcomes.

An integrated approach to evidence generation is critical to optimize strategic value stories and achieve commercialization goals. A virtuous cycle of evidence generation and value delivery is woven together by insights from randomized clinical trial and real world evidence approaches to produce poignant evidence that meets decision maker needs.

Trinity’s Evidence Strategy team achieves accuracy and confidence in identifying the right patients by using the most appropriate data assets, analytics and analytical rigor to drive the evidence needed, including Trinity’s unique network of direct data access. Trinity’s integrated, tech-enabled approach allows clients to tap into dedicated, experienced HEOR and RWE teams for support:

• Demonstrate product differentiation
• Conduct appropriate statistical testing and comparator analyses—including matched cohort/baseline/reference
• Identify compelling economic evidence to support payer engagement
• Develop compelling clinical and humanistic evidence to support medical education

Which data sources have the greatest utility for each specific asset?

How—and when—
can they be
leveraged?

How should
they be combined?

What changes in data sources will influence healthcare in the future?

Our Team

Trinity’s Evidence Strategy team features advanced degrees including multiple PhD-level experts – we consistently deliver high-quality insights and products to meet internal and external stakeholder needs. 

Meet Our Evidence Strategy Experts

The team is led by an Nandini Hadker, an Economist who presents annually at ISPOR, ISPOR-EU, AMCP, AMCP-Nexus and strategic clinical conferences who has authored numerous white papers, academic research posters and peer-reviewed manuscripts in reputed journals.  

Nandini Hadker is supported by Matt O’Hara and Jeff Skaar, who are also leaders in the evidence generation and HEOR space and bring deep expertise in the sphere of HEOR, evidence generation and scientific dissemination.